| Kranus Health–Karista: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-lead investor Karista |
2023-10-02 |
| Kranus Health–SEVERAL: investment, 202310 financing round Series A expansion approx $8.5m bringing total Series A to $15m |
2023-10-02 |
| Kranus Health–Wenvest: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor Wenvest |
2023-10-02 |
| AexeRNA Therapeutics–BioNTech: investment, 202310 acquisition €na of AexeRNA by BioNTech |
2023-10-01 |
| Mainz Biomed–Cantor Fitzgerald: investor conference, 202309 supply service Mainz Biomed presents at CF Global Healthcare Conference 2023 in NY |
2023-09-28 |
| 4SC–Optimum Strategic Communications: public relations, 202309 service existent by Optimum |
2023-09-27 |
| Co.faktor–Cytel: investment, 202309 acquisition of Co.faktor GmbH by Cytel Inc |
2023-09-26 |
| Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202309–203309 supply 10y >$100m of nca lutetium-177 to Point Biopharma |
2023-09-25 |
| Traceless Materials–b.value: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor b.value |
2023-09-25 |
| Traceless Materials–GLS Bank: investment, 202309 financing round Series A totalling €36.6m incl new + co-investor GLS Bank Hamburg |
2023-09-25 |
| Traceless Materials–High-Tech Gründerfonds: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor HTGF |
2023-09-25 |
| Traceless Materials–Planet A: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor Planet A Ventures |
2023-09-25 |
| Traceless Materials–SEVERAL: investment, 202309 financing round Series A €36.6m led by UB FIGG plus other new + all existing investors |
2023-09-25 |
| Traceless Materials–Sparkassen (DE): investment, 202309 financing round Series A totalling €36.6m incl new + co-investor HaSpa |
2023-09-25 |
| Traceless Materials–SWEN Capital Partners: investment, 202309 financing round Series A totalling €36.6m incl new + co-lead investor Blue Ocean fund |
2023-09-25 |
| Traceless Materials–United Bankers: investment, 202309 financing round Series A totalling €36.6m incl new + lead investor UB FIGG |
2023-09-25 |
| CARTemis Therapeutics–Germany (govt): grant, 202309c– BMBF grant €1.3m for clinical trials with CAR T-cell therapy targeting BCMA |
2023-09-21 |
| CARTemis Therapeutics–Helmholtz: investment, 202309 existent financing from Helmholtz Association spin-off fund |
2023-09-21 |
| Mainz Biomed–MC Services: public relations, 202309 service existent by MC Services |
2023-09-20 |
| Merck (DE)–BenevolentAI: AI-based drug discovery, 202309– strategic collab up to $594m plus royalties incl low 2-digit-$m upfront |
2023-09-20 |
| Merck (DE)–Exscientia: AI-based drug discovery, 202309– collab $20m upfront + $674m milestones plus royalties |
2023-09-20 |
| SHS Capital–SEVERAL: investment, 202309 final closing of SHS VI fund adding ca €50 after first close bringing total fund size to €270m |
2023-09-13 |
| Grande Bio-tech–Oncgnostics: molecular diagnostics, 202309– distribution of early cancer detection tests developed by Oncgnostics in ASEAN countries |
2023-09-05 |
| Oncgnostics–Grande Bio-tech: investment, 202309 financing round totalling €7-digit incl lead investor Grande Bio-tech Co Ltd with €7-digit investment |
2023-09-05 |
| Oncgnostics–High-Tech Gründerfonds: investment, 202309 financing round totalling €7-digit incl existing + co-investor HTGF |
2023-09-05 |
| Oncgnostics–SEVERAL: investment, 202309 financing round €7-digit led by Grande Bio-tech Co Ltd + incl bm-t + HTGF |
2023-09-05 |
| Oncgnostics–Thuringia (govt): investment, 202309 financing round totalling €7-digit incl existing + co-investor bm-t |
2023-09-05 |
| CrystalsFirst–Helmholtz: drug discovery technology, 202309–202410 collab developm in joint project LigandML with DESY with funding from IFB Hamburg |
2023-09-01 |
| Takara Shuzo–Eppendorf: lab automation equipment, 202308– collab strategic co-marketing agreem automating Takara Bio chemistries on epMotion platforms |
2023-08-25 |
| AbbVie–Temedica: digital patient companion app, 202308 collab launch of companion app Tami for patients with chronic IBD in Germany |
2023-08-02 |
| Bind-X–Greeneering Invest: investment, 202308 financing round Series B totalling €10m incl new investor Greeneering Invest |
2023-08-01 |
| Bind-X–Heritage Group: investment, 202308 financing round Series B totalling €10m incl new investor HG Ventures |
2023-08-01 |
| Bind-X–High-Tech Gründerfonds: investment, 202308 existing investor HTGF |
2023-08-01 |
| Bind-X–K&K 1: investment, 202308 financing round Series B totalling €10m incl new investor K&K 1 |
2023-08-01 |
| Bind-X–Saxovent: investment, 202308 financing round Series B totalling €10m incl new investor Saxovent Smart Eco Investments |
2023-08-01 |
| Bind-X–SEVERAL: investment, 202308 financing round Series B €10m with HG Ventures + K&K1 + Greeneering Invest + Saxovent |
2023-08-01 |
| Bind-X–Vantage Value: investment, 202308 existing investor Vantage Value |
2023-08-01 |
| BioNTech–Duality Biologics: antibody-drug conjugates, 202308– license excl ww excl China? to develop + manufacture + commercialise DB-1305 |
2023-08-01 |
| Cellbox Solutions–EU (govt): grant, 202308–202507 EIC Accelerator grant €2.5m |
2023-08-01 |
| AaviGen–Hopp Group: investment, 202307 financing round Series B €17m from existing investor DH-LT Investments GmbH |
2023-07-26 |
| Crescendo Biologics–BioNTech: investment, 202307 financing round totalling $32m incl existing investor BioNTech |
2023-07-24 |
| CrystalsFirst–NexMR: fragment-based drug discovery, 202307– collab combining crystallography technology with NRM for drug discovery |
2023-07-24 |
| Epigenomics–New Day Diagnostics: investment, 202307– acquisition of substantially all assets up to $12.05m plus license + milestones by New Day SIGNED |
2023-07-24 |
| LimmaTech Biologics–Trophic Communications: public relations, 202307 service existent by Trophic |
2023-07-20 |
| Mage Biologics–TVM: investment, 202307– Mage Biologics launches with up to $28m to be invested by Tillotts Pharma + TVM LSI II |
2023-07-20 |
| TVM–MC Services: public relations, 202307 service existent by MC Services |
2023-07-20 |
| BioNTech–Biotheus: antibody cancer drug, 202307– strategic research collab + ww excl option + license agreement |
2023-07-19 |
| BioNTech–Biotheus: antibody cancer drug, 202311– collab + license ww excl ex-Greater China for PM8002 $55m upfront + >$1b milestones + royalties |
2023-07-19 |
| Leon-Nanodrugs–MC Services: public relations, 202307 service existent by MC Services |
2023-07-18 |
| AATec Medical–SEVERAL: investment, 202307 seed financing round €2.7m from private investors + industry experts + family offices |
2023-07-17 |
| Vertama–BACB: investment, 202307 seed financing round totalling 7-digit € incl investor Berlin Angel Fund |
2023-07-12 |
| Vertama–High-Tech Gründerfonds: investment, 202307 seed financing round totalling 7-digit € incl lead investor HTGF |
2023-07-12 |
| Vertama–OTHER: investment, 202307 seed financing round totalling 7-digit € incl renowned business angels |
2023-07-12 |
| Vertama–SEVERAL: investment, 202307 seed financing round 7-digit € led by HTGF |
2023-07-12 |
| Celares–Biosynth: investment, 202307 acquisition of Celares by Biosynth |
2023-07-11 |
| Mallia Therapeutics–MC Services: public relations, 202307 service existent by MC Services |
2023-07-11 |
| Mallia Therapeutics–SEVERAL: investment, 202307c– seed financing round raising ongoing 7/23 |
2023-07-11 |
| BioNTech–Doer Biologics: biopharmaceuticals, 202308– license ww to use Doer Bio discovery to develop + market biotherapeutics against one target |
2023-07-10 |
| TolerogenixX–Akampion: public relations, 202307 service existent by Akampion |
2023-07-06 |
| TolerogenixX–Bruchmann Group: investment, 202307 financing round Series A 2nd closing totalling €7m incl new investor DB Speciality |
2023-07-06 |
| TolerogenixX–SEVERAL: investment, 202307 financing round Series A 2nd closing €7m bringing total round to €11.6m |
2023-07-06 |
| Zoetis–Numaferm: peptide technology, 202307– license + collab €na using peptein technology for RnD of veterinary therapeutics |
2023-07-06 |
| Acousia Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam |
2023-07-05 |
| Cellbox Solutions–Akampion: public relations, 202307 service existent by Akampion |
2023-07-05 |
| inContAlert–SEVERAL: investment, 202307 pre-seed financing round €1.5m led by HTGF + Bayern Kapital + Carma Fund |
2023-07-01 |
| Emergence Therapeutics–Lilly: investment, 202306 acquisition 100% of Emergence Therapeutics AG by Eli Lilly |
2023-06-29 |
| Docflix–SEVERAL: investment, 202306 seed financing round €2m led by HTGF + Brandenburg Kapital |
2023-06-27 |
| Hema.to–SEVERAL: investment, 202306 seed financing round €3.6m with Elaia Partners + Heal Capital + HTGF |
2023-06-26 |
| MESI–SHS Capital: investment, 202306 investment €18m by SHS in MESI |
2023-06-22 |
| Innovative Health Initiative–Thermosome: targeted cancer therapy, 202306– Thermosome is partner in IMAGIO project of IHI |
2023-06-20 |
| Thermosome–Innovative Health Initiative: grant, 202306– funding €1.3m as partner in IMAGIO project of IHI |
2023-06-20 |
| DNTox–SEVERAL: investment, 202306 seed financing round €1.4m led by HTGF |
2023-06-14 |
| Dynamic42–OTHER: investment, 202306 financing round Series A totalling mid-7-figure € incl a family office from the health sector |
2023-06-13 |
| Dynamic42–SEVERAL: investment, 202306 financing round Series A mid-7-figure € incl investors bm-t + a familly office |
2023-06-13 |
| Dynamic42–Thuringia (govt): investment, 202306 financing round Series A totalling mid-7-figure € incl existing investor bm-t |
2023-06-13 |
| OntoChem–Holtzbrinck: investment, 202306 acquisition 100% of OntoChem by Digital Science |
2023-06-07 |
| ITM–SEVERAL: investment, 202306 financing round €255m led by Temasek |
2023-06-05 |
| Sartorius–Waters: biopharma production technology, 202306– collab expansion integration of PATROL UPLC PAS with Resolute BioSMB platform |
2023-06-05 |
| Bico–Swiss Life: real estate, 202306– leaseback 15y of property in Berlin by Scienion from BEOS Light Industrial Germany I fund |
2023-06-01 |
| Swiss Life–Bico: real estate, 202306 acquisition €21m of new Scienion property in Berlin by BEOS Light Industrial Germany I fund |
2023-06-01 |
| Theragnostics–Ariceum Therapeutics: investment, 202306 acquisition 100% of Theragnostics Ltd for $2.5m cash upfront plus $41.5m milestones |
2023-06-01 |
| CARTemis Therapeutics–Germany (govt): grant, 202305– BMBF grant €4.6m to develop CAR T-cell therapy targeting CXCR5 (to MDC+Charité) |
2023-05-26 |
| Prosion–10xDNA: investment, 202205 existent 7-figure seed investment by 10xDNA |
2023-05-23 |
| Smartbax–Boehringer: investment, 202305 seed financing round totalling €1.2m incl existing investor BIVF |
2023-05-23 |
| Smartbax–High-Tech Gründerfonds: investment, 202305 seed financing round totalling €1.2m incl new investor HTGF |
2023-05-23 |
| Smartbax–SEVERAL: investment, 202305 seed financing round €1.2m from BIVF + HTGF |
2023-05-23 |
| Smartbax–Trophic Communications: public relations, 202305 service existent by Trophic |
2023-05-23 |
| Traceless Materials–Germany (govt): grant, 202305– BMUV funding €5.1m for construction of demonstration plant |
2023-05-19 |
| Dualyx–High-Tech Gründerfonds: investment, 202305 financing round Series A totalling €40m incl existing + co-investor HTGF |
2023-05-15 |
| Exazyme–AIX Ventures: investment, 202305 seed financing round totalling €2m from AIX Ventures + Atlantic Labs |
2023-05-15 |
| Exazyme–Altantic Labs: investment, 202305 seed financing round totalling €2m from AIX Ventures + Atlantic Labs |
2023-05-15 |
| Exazyme–SEVERAL: investment, 202305 seed financing round €2m from AIX Ventures + Atlantic Labs |
2023-05-15 |
| Nia Health–Adesso: investment, 202305 seed financing round totalling €3.5m incl co-investor Adesso Ventures |
2023-05-15 |
| Nia Health–High-Tech Gründerfonds: investment, 202305 seed financing round totalling €3.5m incl lead investor HTGF |
2023-05-15 |
| Nia Health–PERSON: investment, 202305 seed financing round totalling €3.5m incl co-investor fund of Kurt Schwarz |
2023-05-15 |
| Nia Health–Piabo PR: public relations, 202305 service existent by Piabo PR |
2023-05-15 |
| Nia Health–SEVERAL: investment, 202305 seed financing round €3.5m led by HTGF |
2023-05-15 |
| Nia Health–Ventura BioMed Investors: investment, 202305 seed financing round totalling €3.5m incl co-investor Venture BioMed Investors |
2023-05-15 |
| Repare Therapeutics–Vivlion: gene editing, 202305– supply of PRICSR CRISPR gRNA libraries for synthetic lethal screening by Vivlion |
2023-05-11 |
| UCB–Ariceum Therapeutics: targeted radiopharmaceuticals, 202305– collab strategic r+d for TRTs for solid tumours + immune-related diseasees |
2023-05-11 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
